AUA2025: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems 

CME Available: https://auau.auanet.org/node/43047

At the conclusion of this activity, participants will be able to:

1. Implement current practice guidelines and explain methods and resources to improve transurethral resection of a bladder tumor (TURBT) skills.

2. Identify the best intravesical agent and duration of therapy for low-, intermediate-, and high-risk NMIBC and what to do during a BCG shortage.

3. Identify methods to treat significant toxicities from various intravesical therapies.

4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.

5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs.

ACKNOWLEDGEMENTS:

This educational activity is supported by an independent educational grants from:

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.